XML 73 R63.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Reporting - Sales from Products (Details) - USD ($) $ in Millions | 3 Months Ended
--- | ---
Mar. 31, 2023 | Mar. 31, 2022
Segment Reporting Information [Line Items] |  |
Sales | $ 14,487 | $ 15,901
Revenue related to the sale of the marketing rights | 51 | 114
Increase (Decrease) In Hedge Revenue | 99 | 69
U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,659 | 7,339
Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,828 | 8,563
Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 14,212 | 15,589
Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,599 | 7,246
Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 7,614 | 8,343
Corporate, Non-Segment |  |
Segment Reporting Information [Line Items] |  |
Sales | 275 | 312
Corporate, Non-Segment | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 60 | 93
Corporate, Non-Segment | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 214 | 220
Pharmaceutical | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 12,721 | 14,107
Pharmaceutical | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,117 | 6,773
Pharmaceutical | Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 6,604 | 7,334
Pharmaceutical | Operating Segments | Keytruda |  |
Segment Reporting Information [Line Items] |  |
Sales | 5,795 | 4,809
Pharmaceutical | Operating Segments | Keytruda | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 3,485 | 2,779
Pharmaceutical | Operating Segments | Keytruda | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 2,310 | 2,030
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza |  |
Segment Reporting Information [Line Items] |  |
Sales | 275 | 266
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 142 | 141
Pharmaceutical | Operating Segments | Alliance revenue - Lynparza | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 133 | 125
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima |  |
Segment Reporting Information [Line Items] |  |
Sales | 232 | 227
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 153 | 156
Pharmaceutical | Operating Segments | Alliance revenue - Lenvima | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 79 | 71
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl |  |
Segment Reporting Information [Line Items] |  |
Sales | 43 | 52
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 30 | 27
Pharmaceutical | Operating Segments | Alliance Revenue - Reblozyl | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 12 | 25
Pharmaceutical | Operating Segments | Welireg |  |
Segment Reporting Information [Line Items] |  |
Sales | 42 | 18
Pharmaceutical | Operating Segments | Welireg | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 41 | 18
Pharmaceutical | Operating Segments | Welireg | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1 | 0
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,972 | 1,460
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 416 | 418
Pharmaceutical | Operating Segments | Gardasil/Gardasil 9 | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,556 | 1,042
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax |  |
Segment Reporting Information [Line Items] |  |
Sales | 528 | 470
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 421 | 371
Pharmaceutical | Operating Segments | ProQuad/M-M-R II/Varivax | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 107 | 99
Pharmaceutical | Operating Segments | RotaTeq |  |
Segment Reporting Information [Line Items] |  |
Sales | 297 | 216
Pharmaceutical | Operating Segments | RotaTeq | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 180 | 175
Pharmaceutical | Operating Segments | RotaTeq | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 117 | 41
Pharmaceutical | Operating Segments | Vaxneuvance |  |
Segment Reporting Information [Line Items] |  |
Sales | 106 | 5
Pharmaceutical | Operating Segments | Vaxneuvance | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 94 | 5
Pharmaceutical | Operating Segments | Vaxneuvance | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 13 | 0
Pharmaceutical | Operating Segments | Pneumovax 23 |  |
Segment Reporting Information [Line Items] |  |
Sales | 96 | 173
Pharmaceutical | Operating Segments | Pneumovax 23 | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 40 | 118
Pharmaceutical | Operating Segments | Pneumovax 23 | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 55
Pharmaceutical | Operating Segments | Vaqta |  |
Segment Reporting Information [Line Items] |  |
Sales | 40 | 36
Pharmaceutical | Operating Segments | Vaqta | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 30 | 29
Pharmaceutical | Operating Segments | Vaqta | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 10 | 7
Pharmaceutical | Operating Segments | Bridion |  |
Segment Reporting Information [Line Items] |  |
Sales | 487 | 395
Pharmaceutical | Operating Segments | Bridion | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 276 | 195
Pharmaceutical | Operating Segments | Bridion | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 210 | 199
Pharmaceutical | Operating Segments | Prevymis |  |
Segment Reporting Information [Line Items] |  |
Sales | 129 | 94
Pharmaceutical | Operating Segments | Prevymis | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 54 | 40
Pharmaceutical | Operating Segments | Prevymis | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 75 | 54
Pharmaceutical | Operating Segments | Primaxin |  |
Segment Reporting Information [Line Items] |  |
Sales | 80 | 58
Pharmaceutical | Operating Segments | Primaxin | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 4 | 1
Pharmaceutical | Operating Segments | Primaxin | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 76 | 58
Pharmaceutical | Operating Segments | Dificid |  |
Segment Reporting Information [Line Items] |  |
Sales | 65 | 52
Pharmaceutical | Operating Segments | Dificid | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 62 | 49
Pharmaceutical | Operating Segments | Dificid | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 3 | 3
Pharmaceutical | Operating Segments | Noxafil |  |
Segment Reporting Information [Line Items] |  |
Sales | 60 | 57
Pharmaceutical | Operating Segments | Noxafil | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 14 | 10
Pharmaceutical | Operating Segments | Noxafil | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 46 | 48
Pharmaceutical | Operating Segments | Zerbaxa |  |
Segment Reporting Information [Line Items] |  |
Sales | 50 | 30
Pharmaceutical | Operating Segments | Zerbaxa | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 27 | 18
Pharmaceutical | Operating Segments | Zerbaxa | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 23 | 12
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo |  |
Segment Reporting Information [Line Items] |  |
Sales | 99 | 72
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 83 | 71
Pharmaceutical | Operating Segments | Alliance revenue - Adempas/Verquvo | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 16 | 1
Pharmaceutical | Operating Segments | Adempas |  |
Segment Reporting Information [Line Items] |  |
Sales | 59 | 61
Pharmaceutical | Operating Segments | Adempas | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Adempas | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 59 | 61
Pharmaceutical | Operating Segments | Lagevrio |  |
Segment Reporting Information [Line Items] |  |
Sales | 392 | 3,247
Pharmaceutical | Operating Segments | Lagevrio | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | (2) | 1,523
Pharmaceutical | Operating Segments | Lagevrio | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 394 | 1,723
Pharmaceutical | Operating Segments | Isentress/Isentress HD |  |
Segment Reporting Information [Line Items] |  |
Sales | 123 | 158
Pharmaceutical | Operating Segments | Isentress/Isentress HD | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 52 | 61
Pharmaceutical | Operating Segments | Isentress/Isentress HD | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 71 | 97
Pharmaceutical | Operating Segments | Belsomra |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 69
Pharmaceutical | Operating Segments | Belsomra | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 16 | 20
Pharmaceutical | Operating Segments | Belsomra | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 40 | 48
Pharmaceutical | Operating Segments | Simponi |  |
Segment Reporting Information [Line Items] |  |
Sales | 180 | 186
Pharmaceutical | Operating Segments | Simponi | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Simponi | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 180 | 186
Pharmaceutical | Operating Segments | Remicade |  |
Segment Reporting Information [Line Items] |  |
Sales | 51 | 61
Pharmaceutical | Operating Segments | Remicade | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 0 | 0
Pharmaceutical | Operating Segments | Remicade | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 51 | 61
Pharmaceutical | Operating Segments | Januvia |  |
Segment Reporting Information [Line Items] |  |
Sales | 551 | 779
Pharmaceutical | Operating Segments | Januvia | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 271 | 325
Pharmaceutical | Operating Segments | Januvia | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 280 | 454
Pharmaceutical | Operating Segments | Janumet |  |
Segment Reporting Information [Line Items] |  |
Sales | 329 | 454
Pharmaceutical | Operating Segments | Janumet | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 56 | 63
Pharmaceutical | Operating Segments | Janumet | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 272 | 391
Pharmaceutical | Operating Segments | Other pharmaceutical |  |
Segment Reporting Information [Line Items] |  |
Sales | 584 | 602
Pharmaceutical | Operating Segments | Other pharmaceutical | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 172 | 160
Pharmaceutical | Operating Segments | Other pharmaceutical | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 414 | 443
Animal Health | Operating Segments |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,491 | 1,482
Animal Health | Operating Segments | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 482 | 473
Animal Health | Operating Segments | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 1,010 | 1,009
Animal Health | Operating Segments | Livestock |  |
Segment Reporting Information [Line Items] |  |
Sales | 849 | 832
Animal Health | Operating Segments | Livestock | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 174 | 171
Animal Health | Operating Segments | Livestock | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | 676 | 661
Animal Health | Operating Segments | Companion Animals |  |
Segment Reporting Information [Line Items] |  |
Sales | 642 | 650
Animal Health | Operating Segments | Companion Animals | U.S. |  |
Segment Reporting Information [Line Items] |  |
Sales | 308 | 302
Animal Health | Operating Segments | Companion Animals | Int’l |  |
Segment Reporting Information [Line Items] |  |
Sales | $ 334 | $ 348

X
- Definition Increase (Decrease) In Hedge Revenue + References No definition available. + Details
Name: | mrk_IncreaseDecreaseInHedgeRevenue
Namespace Prefix: | mrk_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The cash inflow from disposal of asset without physical form usually arising from contractual or other legal rights, excluding goodwill. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=126954810&loc=d3e3179-108585 + Details
Name: | us-gaap_ProceedsFromSaleOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 323 -SubTopic 10 -Section 50 -Paragraph 3 -Subparagraph (c) -URI https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 28 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 235 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -URI https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690 Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 235 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -URI https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884 Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756 Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 470 -SubTopic 10 -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -URI https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756 Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(1)) -URI https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227 + Details
Name: | us-gaap_Revenues
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_SegmentReportingInformationLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_StatementGeographicalAxis=country_US
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementGeographicalAxis=mrk_InternationalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_PharmaceuticalsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_KeytrudaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AlliancerevenueLynparzaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LenvimaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueReblozylMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_WeliregMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_GardasilGardasil9Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ProQuadMMRIIVarivaxMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RotateqMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaxneuvanceMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_Pneumovax23Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_VaqtaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BridionMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrevymisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_PrimaxinMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_DificidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_NoxafilMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_ZerbaxaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AllianceRevenueAdempasVerquvoMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_AdempasMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LagevrioMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_IsentressIsentressHDMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_BelsomraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_SimponiMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_RemicadeMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanuviaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_JanumetMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_OtherPharmaceuticalMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_StatementBusinessSegmentsAxis=mrk_AnimalHealthsegmentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_LivestockMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=mrk_CompanionAnimalsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |